Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
Status:
Recruiting
Trial end date:
2030-03-31
Target enrollment:
Participant gender:
Summary
The prognosis of pancreatic cancer is extremely poor, even in those patients who had
underwent surgery, the 5-year survival is still less than 10%. Current guidelines recommend
Gemcitabine monotherapy for R0 resection of pancreatic cancer. Inflammation plays an critical
role in the development and progression of pancreatic cancer. Here we intend to assess the
synergistic effect of using celecoxib in combination with gemcitabine on the treatment of R0
resection of pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University